Partnership Knight Therapeutics and Helsinn Healthcare SA expand relationship and enter into exclusive license, distribution, and supply agreement for Onicit®
Partnership Helsinn Group and ESTEVE sign a partnership agreement renewal to commercialize AKYNZEO® and ALOXI® in Germany
Partnership Helsinn attends EORTC annual meeting 2024 with a focus on Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL)
Partnership Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN® and MESULID® in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic
Partnership Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV in The Oncologist
Partnership Helsinn publishes new data evaluating chlormethine gel’s mode of action in Dermatology and Therapy
